IMMUNOCELLULAR THERAPEUTICS's ticker is IMUC and the CUSIP is 452536105. A total of 39 filers reported holding IMMUNOCELLULAR THERAPEUTICS in Q4 2013. The put-call ratio across all filers is 0.48 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $10,000 | -64.3% | 90,379 | -27.6% | 0.00% | – |
| Q2 2016 | $28,000 | -3.4% | 124,881 | +23.2% | 0.00% | – |
| Q1 2016 | $29,000 | -19.4% | 101,378 | 0.0% | 0.00% | – |
| Q4 2015 | $36,000 | -16.3% | 101,378 | 0.0% | 0.00% | – |
| Q3 2015 | $43,000 | -10.4% | 101,378 | 0.0% | 0.00% | – |
| Q2 2015 | $48,000 | +6.7% | 101,378 | +10.2% | 0.00% | – |
| Q1 2015 | $45,000 | -32.8% | 92,013 | 0.0% | 0.00% | – |
| Q4 2014 | $67,000 | -18.3% | 92,013 | 0.0% | 0.00% | – |
| Q3 2014 | $82,000 | -60.2% | 92,013 | -50.0% | 0.00% | – |
| Q2 2014 | $206,000 | +83.9% | 184,026 | +101.0% | 0.00% | – |
| Q1 2014 | $112,000 | +31.8% | 91,560 | 0.0% | 0.00% | – |
| Q4 2013 | $85,000 | -81.9% | 91,560 | -50.0% | 0.00% | – |
| Q3 2013 | $470,000 | +164.0% | 183,120 | +100.0% | 0.00% | – |
| Q2 2013 | $178,000 | – | 91,560 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 4,443,914 | $1,579,000 | 0.09% |
| CHELSEA COUNSEL CO | 28,000 | $10,000 | 0.00% |
| Ifrah Financial Services, Inc. | 18,500 | $7,000 | 0.00% |
| Gerstein Fisher | 13,000 | $5,000 | 0.00% |
| Renaissance Technologies | 1,407,200 | $500,000 | 0.00% |
| CITIGROUP INC | 31,700 | $11,000 | 0.00% |
| GOLDMAN SACHS GROUP INC | 19,012 | $7,000 | 0.00% |
| Catamount Wealth Management | 1,000 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 439,847 | $156,000 | 0.00% |
| GUGGENHEIM CAPITAL LLC | 19,166 | $7,000 | 0.00% |